Organization · Venture Capital
Sangel Capital
Sangel Capital is a prominent biomedical venture capital firm based in Shenzhen, China, specializing in life sciences investments. The firm has a global presence with offices in major cities and focuses on innovative growth enterprises in the biomedical sector.
Overview
What Sangel Capital does
What Sangel Capital is
Sangel Capital is a prominent biomedical venture capital firm based in Shenzhen, China, specializing in life sciences investments. The firm has a global presence with offices in major cities and focuses on innovative growth enterprises in the biomedical sector.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2010
- Approximate age
- About 16 years
- Structured capabilities
- Funder
- Last reviewed
- March 27, 2026
Official channels
Find Sangel Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Sangel Capital as a funder
Investment thesis
Sangel Capital focuses exclusively on the biomedical sector, emphasizing original innovation and core technological assets. The firm adopts a long-term investment philosophy, prioritizing value creation over mere exit strategies.
Focus narrative
Sangel Capital specializes in investments within the life sciences sector, targeting innovative growth enterprises with significant capital value and commercial potential. The firm aims to cultivate industry benchmarks in promising industries, focusing on biomedicine, medical devices, healthcare, and pharmaceuticals.
Value beyond capital
Sangel Capital provides significant value to its portfolio companies through its extensive industry expertise, project resources, and a long-term investment approach. The firm's presence in both domestic and international markets facilitates cross-border investments and collaborations, enhancing growth opportunities for its portfolio companies.
Focus and fit
- Stages
- Seed · Pre-seed · Series A
- Regions
- Asia · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 70
- Recorded notable exits
- Huaheng Biotech and Sirnaomics Ltd
Portfolio context
Sangel Capital has invested in over 70 notable companies in the life sciences sector, including: Huaheng Biotech: Achieved IPO on the Shanghai STAR Market. Sirnaomics Ltd: Listed on the Hong Kong Stock Exchange, specializing in siRNA therapeutics. 3D Medicines: Focused on oncology with an IPO planned. BeyondSpring: Oncology company with an IPO planned. Denovo Biopharma: Precision oncology with an IPO planned. InnerMed: Engaged in medical devices. Yinyi Biotech: Active in the biotech space. Ascentawits Pharmaceuticals: Focused on pharmaceuticals. Magpie Pharmaceuticals: Engaged in pharmaceutical development.
Common questions
What to know about Sangel Capital
Upseed classifies Sangel Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 27, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.